Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:

NCT ID: NCT03080571 Completed - Ischemic Stroke Clinical Trials

Intraarterial Stem Cells in Subacute Ischemic Stroke

Start date: July 2015
Phase: Phase 1
Study type: Interventional

Stroke is a leading cause of morbidity and mortality.Acute ischemia causes irreversible damage to neurons and glial cells, leading to functional deficits and chronic sequelae with variable degrees of spontaneous recovery of function. Stem cells have been shown to enhance recovery through multiple immunomodulatory effects, neoangiogenesis and neurogenesis. We conducted a prospective randomised end observer blinded study to evaluate primarily the safety of intraarterial autologous stem cells delivered to ipsilateral middle cerebral artery in acute and subacute stroke patients (0-15 days post ictus).Secondarily we aimed to evaluate the outcome on the basis of clinical evaluation and follow up imaging

NCT ID: NCT03079739 Completed - Myocardial Ischemia Clinical Trials

Long-term Outcome of Deferred Lesion Based on FFR

HALE-BOPP
Start date: March 1, 2017
Phase:
Study type: Observational [Patient Registry]

Treatment of ischemic myocardium with percutaneous coronary intervention (PCI) in addition to optimal medical therapy reduces major adverse cardiac events. However, less than half of patients have a noninvasive ischemic evaluation before revascularization. Fractional flow reserve (FFR) can determine the hemodynamic significance of a coronary lesion by measuring the distal mean coronary and aortic pressures during maximal hyperemia. Previous studies conducted principally in stable coronary artery disease (CAD) patients have demonstrated that FFR-guided revascularization improves clinical outcomes, quality of life, and cost-efficiency. However, the reliability and safety of FFR assessment in different setting than stable CAD is unclear. In addition, the majority of studies are performed with the only one device. No data are available from other clinically used devices. The HALE BOPP registry is an investigator-initiated observational study, designed to prospectively include all patients referred for coronary angiography in which at least 1 lesion was evaluated by FFR.

NCT ID: NCT03079167 Completed - Clinical trials for Hypoxic-Ischemic Encephalopathy

PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns

PAEAN
Start date: May 14, 2016
Phase: Phase 3
Study type: Interventional

Double-blind, placebo controlled Phase III trial of erythropoietin for hypoxic ischaemic encephalopathy in infants receiving hypothermia. The study aim is to determine whether Epo in conjunction with hypothermia in infants with moderate/severe hypoxic ischaemic encephalopathy (HIE) will improve neurodevelopmental outcomes at 2 years of age, without significant adverse effects, when compared to hypothermia alone.

NCT ID: NCT03076801 Completed - Clinical trials for Myocardial Infarction

Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?

CHOIR
Start date: September 25, 2017
Phase: N/A
Study type: Interventional

This pilot randomized control trial will examine the role of choral singing on psychosocial stress and cardiovascular outcomes in patients with ischemic heart disease (IHD). The hypothesis is that choral singing will improve psychosocial stress in comparison to the control group and this may have an impact on rates of hospitalization, death, myocardial infarction and stroke in these patients.

NCT ID: NCT03076476 Completed - Myocardial Ischemia Clinical Trials

Coronary Microcirculatory and Bioresorbable Vascular Scaffolds

EMPIRE-BVS
Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Angina and heart attacks are caused by narrowings in the coronary arteries (blood vessels) supplying the heart. These narrowings can be opened using a balloon and stent (angioplasty). Traditionally, stents are constructed from metal and are permanent. However, newer stents are being constructed from carbohydrate polymers (scaffolds), which allow them to reabsorb over time leaving no permanent implant. New data has suggested that these scaffolds appear to reduce recurrent angina and may alter the blood flow down the artery. However, it is not known whether this is due to the scaffolds themselves or the way the scaffolds are inserted. In this study we hope to measure the blood flow to the heart and assess changes in that flow during stent and scaffold insertion. It is also important to know whether these effects are durable and thus, a cohort of patients will return at 3-months to be restudied. These data are important to help us understand why blood flow is affected by stent/scaffold selection or device implantation technique and whether this results in better long-term outcomes.

NCT ID: NCT03072914 Completed - Moyamoya Disease Clinical Trials

Effects of Remote Ischemic Preconditioning With Postconditioning on Neurologic Outcome

Start date: March 7, 2017
Phase: N/A
Study type: Interventional

In the present study, we evaluated whether RIPC with RIPostC reduce the major neurocomplication in patients undergoing STA-MCA anastomosis.

NCT ID: NCT03057080 Completed - Clinical trials for Ischemic Foot Ulcers

The Role of Percutaneous Angioplasty in Ischemic Leg Ulcer Healing

Start date: June 1, 2009
Phase: N/A
Study type: Interventional

The aim of our study was to evaluate the technical and clinical effectiveness of PTA in the management of ischemic foot ulcers. All consecutive patients presenting with a foot ulcer at the outpatient Vascular surgery clinic of our hospital were evaluated. If non-invasive parameters suggested peripheral arterial disease (PAD) anatomic imaging (CTA and/or DSA) was performed and a PTA was carried out when feasible during the same session. All patients were followed until healing, amputation, death, or for at least two years. Short-term and long-term clinical success of PTA was evaluated based on ulcer size and appearance. Patients with worsening ulcers after PTA underwent bypass grafting or amputation.

NCT ID: NCT03053128 Completed - Cardiac Ischemia Clinical Trials

Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease

CSWT
Start date: January 20, 2017
Phase: N/A
Study type: Interventional

Coronary heart disease (CHD) is a public health care challenge. There are three types of treatment for CHD, medication, percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG). However, some end-stage CHD patients lost the chance to get those treatment. Cardiac shock wave therapy (CSWT) is a new developed therapy for these patients, which is used in tens of countries all over the world. Safety, invasiveness, effectiveness is its advantage. Ischemia condition can be improved after CSWT. There are only three cities in China run the program of CSWT, which are Kunming, Beijing and Shanghai. The investigators designed a randomized double-blind study to evaluate the effectiveness and safety of CSWT.

NCT ID: NCT03052803 Completed - Clinical trials for Coronary Artery Disease

Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries

FFR-DS
Start date: February 1, 2017
Phase: N/A
Study type: Observational

The aim of the study is to compare different devices available to measure fractional flow reserve (FFR) in coronary arteries.

NCT ID: NCT03052530 Completed - Clinical trials for Coronary Artery Disease

Sapphire II PRO US Clinical Study

Start date: May 5, 2017
Phase: N/A
Study type: Interventional

A prospective, open label, multi-center, single arm, observational study designed to evaluate the acute safety and device procedural success of the Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters in subjects with stenotic coronary arteries or bypass grafts during percutaneous coronary intervention. Sixty (60) subjects will be treated at up to 5 U.S. sites with the Sapphire II PRO diameters 1.0 and 1.25 mm PTCA dilatation catheters to pre-dilate coronary arteries or bypass grafts during their index procedure. All subjects will be screened according to the protocol inclusion and exclusion criteria and will be followed through hospital discharge.